Formulation and In-Vitro/Ex-Vivo Characterization of Pregelled Hybrid Alginate-Chitosan Microparticles for Ocular Delivery of Ketorolac Tromethamine.
alginate
chitosan
hybrid microparticles
ketorolac
lens cell lines
permeation
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
21 Jun 2023
21 Jun 2023
Historique:
received:
20
05
2023
revised:
13
06
2023
accepted:
19
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Innovative hybrid chitosan-sodium alginate (Ch-Ag) microparticles (MPs) were fabricated using both the ionic gelation method as well as the pre-gelation technique. The hybrid Ch-Ag MPs were studied for size, zeta potential, morphology, mucoadhesion, in-vitro release, corneal permeation, and ocular irritation using lens and corneal epithelial cell lines. The average particle size ranged from 1322 nm to 396 nm. The zeta potential for the prepared formulations showed an increase with increasing Ch concentrations up to a value of >35 mV; the polydispersity index (PDI) of some optimized MPs was around 0.1. Compared to drug-free MPs, ketorolac-loaded Ch-Ag MPs demonstrated a drug proportion-dependent increase in their size. SEM, as well as TEM of KT-loaded MPs, confirmed that the formed particles were quasi-spherical to elliptical in shape. The KT release from the MPs demonstrated a prolonged release profile in comparison to the control KT solution. Further, mucoadhesion studies with porcine mucin revealed that the KT-loaded MPs had effective mucoadhesive properties, and polymeric particles were stable in the presence of mucin. Corneal permeation was studied on bovine eyes, and the results revealed that Ch-based MPs were capable of showing more sustained KT release across the cornea compared with that for the control drug solution. Conclusively, the cytotoxicity assay confirmed that the investigated MPs were non-irritant and could confer protection from direct drug irritation of KT on the ocular surface. The MTT cytotoxicity assay confirmed that KT-loaded MPs showed acceptable and reasonable tolerability with both human lens and corneal epithelial cell lines compared to the control samples.
Identifiants
pubmed: 37447419
pii: polym15132773
doi: 10.3390/polym15132773
pmc: PMC10346322
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Deanship of Scientific Research at King Khalid University
ID : RGP2/55/44
Références
Nanomaterials (Basel). 2022 Jan 06;12(2):
pubmed: 35055206
Cornea. 2006 Jan;25(1):55-60
pubmed: 16331043
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1416-25
pubmed: 16565375
Drug Saf. 2002;25(4):233-50
pubmed: 11994027
Eur J Pharm Biopharm. 2008 Mar;68(3):513-25
pubmed: 17983737
Adv Drug Deliv Rev. 2021 Oct;177:113957
pubmed: 34481032
Adv Drug Deliv Rev. 2023 Mar;194:114721
pubmed: 36773886
AAPS J. 2008 Jun;10(2):229-41
pubmed: 18437583
Surv Ophthalmol. 2010 Mar-Apr;55(2):108-33
pubmed: 20159228
Mol Vis. 2012;18:1973-82
pubmed: 22876124
J Pharm Sci. 2011 May;100(5):1833-46
pubmed: 21246556
Colloids Surf B Biointerfaces. 2018 Nov 1;171:406-412
pubmed: 30071482
Drug Discov Today. 2014 Apr;19(4):400-12
pubmed: 24120893
J Pharm Sci. 1993 Sep;82(9):912-7
pubmed: 8229689
Compr Rev Food Sci Food Saf. 2021 Nov;20(6):5345-5369
pubmed: 34596328
Int J Biol Macromol. 2020 May 1;150:559-572
pubmed: 32057864
Drug Dev Ind Pharm. 2016;42(4):514-24
pubmed: 26407208
Int J Nanomedicine. 2016 Jun 14;11:2815-27
pubmed: 27366062
Pharm Res. 2004 May;21(5):803-10
pubmed: 15180338
Ophthalmic Res. 2010;43(4):208-16
pubmed: 20068374
Curr Eye Res. 2009 Aug;34(8):698-705
pubmed: 19899997
J Colloid Interface Sci. 2023 May 15;638:616-628
pubmed: 36774875
Int J Pharm. 2000 Nov 19;209(1-2):1-14
pubmed: 11084241
Hum Exp Toxicol. 2019 Aug;38(8):983-991
pubmed: 31064220
J Control Release. 2001 Jan 29;70(1-2):1-20
pubmed: 11166403
J Nanosci Nanotechnol. 2007 Aug;7(8):2833-41
pubmed: 17685304
J Microencapsul. 1997 Jan-Feb;14(1):101-12
pubmed: 8994079
J Biomater Sci Polym Ed. 2005;16(1):43-56
pubmed: 15796304
J Control Release. 2001 Feb 23;70(3):399-421
pubmed: 11182210
Pharm Res. 2007 Dec;24(12):2198-206
pubmed: 17577641